Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
58.88
-0.68 (-1.14%)
Delayed Quote
Updated: 1:34 PM EST, Nov 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026
Today 6:59 EST
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
November 18, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Evolution of Research & Development Organization
November 12, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
November 06, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
October 29, 2026
From
Bristol Myers Squibb
Via
Business Wire
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
October 26, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
October 23, 2026
From
Bristol Myers Squibb
Via
Business Wire
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
October 23, 2026
From
Pathos AI
Via
Business Wire
Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
October 23, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
October 19, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
October 12, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
October 12, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
October 08, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
October 01, 2026
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
September 30, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
September 25, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
September 18, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
September 17, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
September 16, 2026
From
Bristol Myers Squibb
Via
Business Wire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via
Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via
Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
From
BioMedWire
Via
GlobeNewswire
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
September 08, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
August 29, 2026
From
Bristol Myers Squibb
Via
Business Wire
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology
From
MarketNewsUpdates.com
Via
GlobeNewswire
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
August 13, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
August 10, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
July 30, 2026
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1